%0 Journal Article
%T Combination TS©\1 plus EGFR©\tyrosine kinase inhibitors (TKIs) for the treatment of non©\small cell lung cancer after progression on first©\line or further EGFR©\TKIs: A phase II, single©\arm trial
%A Junling Li
%A Lu Yang
%A Sheng Yang
%A Xingsheng Hu
%A Yalei Wang
%A Yan Wang
%A Yan Zhang
%A Yutao Liu
%J Archive of "Thoracic Cancer".
%D 2018
%R 10.1111/1759-7714.12632
%X EGFR©\tyrosine kinase inhibitors (TKIs) combined with TS©\1 might overcome EGFR©\TKI resistance, which has been indicated by several preclinical studies. We investigated the synergistic efficacy and safety of the combination therapy of EGFR©\TKIs and TS©\1 in non©\small cell lung cancer (NSCLC) patients with acquired resistance to previous EGFR©\TKI therapy
%K Acquired resistance
%K EGFR©\tyrosine kinase inhibitors
%K non©\small cell lung cancer
%K phase II study
%K TS©\1
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983211/